None listed
Conditions
Brief summary
The aims of our study were to evaluate the correlation between sex hormone levels and tear film osmolarity in postmenopausal women and to assess the efficacy of an oral phytoestrogen supplement in controlling the ocular symptoms of post-menopausal dysfunctional tear syndrome (DTS).
Interventions
Sixty-six postmenopausal women with dysfunctional tear syndrome (DTS) were enrolled in a randomized, double-blind, placebo-controlled, cross-over study. Patient were divided into two groups (Group A and Group B) and treated respectively with Lacrisek ( alpha lipoic acid100mg,phytoestrogen 200mg, fish oil 240mg),Registered Trademark, tablets or placebo tablets, twice a day for 30 days. The two treatment periods were separated by a 30-day washout. Patients were examined on day 0 and day 30 of ea
Sixty-six postmenopausal women with dysfunctional tear syndrome (DTS) were enrolled in a randomized, double-blind, placebo-controlled, cross-over study. Patient were divided into two groups (Group A and Group B) and treated respectively with Lacrisek ( alpha lipoic acid100mg,phytoestrogen 200mg, fish oil 240mg),Registered Trademark, tablets or placebo tablets, twice a day for 30 days. The two treatment periods were separated by a 30-day washout. Patients were examined on day 0 and day 30 of each period. Assessments included blood levels of sex hormones, the Schirmer test for tear production, and measurement of tear osmolarity and tear film break-time (T-BUT).
Sponsors
ministry of education university and research
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
48 Years to No maximum
Healthy volunteers
No
Inclusion criteria
menopause and severe dry eye syndrome. Dry eye syndrome is defined as a multifactorial disorder caused by one chronic inflammatory status due to tear film disequilibrium, main symptoms are: photophobia, visual disturbance, extraneous body sensation, difficulties in eye opening at the morning.
Exclusion criteria
Hypersensitivity to one of components of the phytoestrogen supplement being tested, autoimmune disease, and current use of topical anti-inflammatory and/or antibiotic eye therapy
Outcome results
None listed